ZNRF3 Overview
Molecule Name
E3 ubiquitin-protein ligase ZNRF3
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
Background
The transmembrane E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) is a negative feedback regulator of Wnt signalling. ZNRF3 is associated with the Wnt receptor complex, and inhibits Wnt signalling by promoting the turnover of frizzled and LRP6 and acts as a tumor suppressor in the intestinal stem cell zone by inhibiting the Wnt signaling pathway.
ZNRF3 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SZN-043 | SZN-043; SWEETS-1 | Phase 1 Clinical | Surrozen Inc | Hepatitis, Alcoholic; Liver Cirrhosis | Details |